Howe & Rusling Inc. Raises Stock Position in AbbVie Inc. $ABBV

Howe & Rusling Inc. raised its holdings in AbbVie Inc. (NYSE:ABBV) by 3.5% during the 2nd quarter, Holdings Channel.com reports. The firm owned 86,365 shares of the company’s stock after acquiring an additional 2,957 shares during the period. AbbVie accounts for 1.2% of Howe & Rusling Inc.’s holdings, making the stock its 22nd biggest holding. Howe & Rusling Inc.’s holdings in AbbVie were worth $16,031,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of ABBV. Marshall & Sullivan Inc. WA purchased a new stake in shares of AbbVie in the second quarter worth about $25,000. TD Capital Management LLC lifted its holdings in AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock valued at $27,000 after acquiring an additional 58 shares during the period. Spurstone Advisory Services LLC acquired a new position in AbbVie in the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. purchased a new stake in AbbVie in the 2nd quarter worth approximately $36,000. Finally, Bear Mountain Capital Inc. grew its stake in shares of AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after purchasing an additional 173 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

ABBV opened at $233.13 on Thursday. The firm’s fifty day simple moving average is $226.27 and its two-hundred day simple moving average is $204.77. AbbVie Inc. has a 52-week low of $164.39 and a 52-week high of $244.81. The company has a market cap of $412.04 billion, a price-to-earnings ratio of 111.02, a PEG ratio of 1.42 and a beta of 0.50. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is 524.24%.

Analyst Ratings Changes

Several research firms recently issued reports on ABBV. Guggenheim boosted their target price on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Wall Street Zen upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research report on Saturday, October 25th. JPMorgan Chase & Co. upped their price objective on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Wells Fargo & Company increased their target price on shares of AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a research note on Friday, September 12th. Finally, Bank of America lifted their price target on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $240.14.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.